ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "monoclonal antibodies and rheumatoid arthritis"

  • Abstract Number: 3222 • 2016 ACR/ARHP Annual Meeting

    Efficacy and Safety of Monotherapy with Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Compared with Adalimumab Monotherapy in Biologic-Naive Patients with Active Rheumatoid Arthritis: Results of a Global, Randomized, Double-Blind, Parallel-Group, Phase 3 Study

    Peter C. Taylor1, Michael Schiff2, Qingmin Wang3, Yusang Jiang3, Regina Kurrasch4, Shruti Daga5, Ravi Rao6, Benjamin Hsu3 and Paul-Peter Tak7, 1Kennedy Institute of Rheumatology, NDORMs, University of Oxford, Oxford, United Kingdom, 2University of Colorado, School of Medicine, Denver, CO, 3Janssen Research & Development, LLC, Spring House, PA, 4GlaxoSmithKline, Collegeville, PA, 5GlaxoSmithKline, Uxbridge, United Kingdom, 6GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom, 7GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom

    Background/Purpose: Sirukumab, a human monoclonal antibody that selectively binds to the cytokine IL-6 with high affinity, is under development for rheumatoid arthritis (RA) and other…
  • Abstract Number: 3223 • 2016 ACR/ARHP Annual Meeting

    Efficacy and Safety of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study

    Daniel Aletaha1, Clifton Bingham III2, Yoshiya Tanaka3, Prasheen Agarwal4, Regina Kurrasch5, Paul-Peter Tak6 and Sharon Popik4, 1Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3University of Occupational and Environmental Health, Kitakyushu, Japan, 4Janssen Research & Development, LLC, Spring House, PA, 5GlaxoSmithKline, Collegeville, PA, 6GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom

    Background/Purpose: Sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity and is under development for rheumatoid arthritis (RA)…
  • Abstract Number: 969 • 2015 ACR/ARHP Annual Meeting

    Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA)

    T. W. J. Huizinga1, Anastas Batalov2, Rumen Stoilov3, Eric Lloyd4, Thomas Wagner5, Didier Saurigny6, Bernard Souberbielle6 and Ehsanollah Esfandiari6, 1Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2UMHAT Kaspela, Plovdiv, Bulgaria, 3University Hospital (MHAT) St Ivan Rilski, Sofia, Bulgaria, 4Takeda Pharmaceuticals, Deerfield, IL, 5Takeda Pharmaceuticals, Zurich, Switzerland, 6Takeda Pharmaceuticals, London, United Kingdom

    Background/Purpose: GM-CSF mediates a range of immunological processes, such as stimulating the production of inflammatory mediators and differentiation of proinflammatory T-helper 17 cells, and may…
  • Abstract Number: 2355 • 2013 ACR/ARHP Annual Meeting

    Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Against The IL-6 Receptor Alpha: Using Acute Phase Reactants, Efficacy and Safety Parameters To Inform Phase 3 Dose Selection

    Janet van Adelsberg1, Steven P. Weinstein2, Neil Graham3, Tanya Momtahen4, Chunpeng Fan5 and Stefano Fiore6, 1Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, 2Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 3Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 4Program Direction, Sanofi, Bridgewater, NJ, 5Biostatistics, Sanofi, Bridgewater, NJ, 6Clinical Science, Sanofi, Bridgewater, NJ

    Background/Purpose: Sarilumab (SAR) is a fully human mAb directed against IL-6Rα. In phase 2 MOBILITY Part A (NCT01061736), SAR administered SC plus MTX (methotrexate 10-25…
  • Abstract Number: 1761 • 2012 ACR/ARHP Annual Meeting

    Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti-CD19 Monoclonal Antibody That Co-Engages the B Cell Antigen Receptor and the FcγRIIb Inhibitory Receptor

    Seung Y. Chu1, Karen Yeter2, Roshan Kotha3, Erik Pong1, Yvonne Miranda1, Hsing Chen1, Sung-Hyung Lee1, Irene Leung1, John R. Desjarlais1, William Stohl2 and David E. Szymkowski4, 1Xencor, Inc., Monrovia, CA, 2Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, 3Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, 4Biotherapeutics, Xencor, Inc., Monrovia, CA

    Background/Purpose: XmAb®5871 is a humanized and Fc-engineered antibody that coengages CD19, part of the B cell receptor (BCR) complex, with the inhibitory receptor FcγRIIb (CD32b).…
  • Abstract Number: L11 • 2012 ACR/ARHP Annual Meeting

    First in Patient Study of Anti-GM-CSF Monoclonal Antibody (MOR103) in Active Rheumatoid Arthritis: Results of a Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Trial

    Frank Behrens1, Mikkel Ostergaard2, Rumen Stoilov3, Piotr Wiland4, Thomas W. Huizinga5, Vadym Y. Berenfus6, Paul-Peter Tak7, Stoyanka Vladeva8, Juergen Rech9, Andrea Rubbert-Roth10, Mariusz Korkosz11, Dmitriy Rekalov12, Igor A. Zupanets13, Bo J. Ejbjerg14, Jens Geiseler15, Julia Fresenius15, Roman P. Korolkiewicz16, Arndt J. Schottelius16 and Harald Burkhardt1, 1CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Germany, 2Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, 3Clinic of rheumatology, University Hospital (MHAT) St. Ivan Rilski, Sofia, Bulgaria, 4Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, 5Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 6Occupational Diseases, Regional Clinical Hospital, Donetsk, Ukraine, 7Academic Medical Center / currently also GlaxoSmithKline, Amsterdam, Netherlands, 8Second Internal Clinic UMHAT Stara Zagora, Stara Zagora, Bulgaria, 9Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 10Internal Medicine I, University of Cologne, Cologne, Germany, 11Malopolskie Centrum Medyczne, Krakow, Poland, 12Department of Internal Diseases, Zaporizhzhia Regional Hospital, Zaporozhe, Ukraine, 13Clinical and Diagnostics Centre of National Pharmaceutical University MOH of Ukraine, Kharkiv, Ukraine, 14Slagelse Sygehus, Slagelse, Denmark, 15Asklepios Clinic Munich-Gauting, Gauting, Germany, 16Development, MorphoSys AG, Martinsried/Planegg, Germany

    Background/Purpose: MOR103, a human mAb targeting GM-CSF, is being evaluated for treatment of rheumatoid arthritis (RA). Pre-clinical studies on cytokine function and investigations in experimental…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology